Quote this publication Share Print

PLEGRIDY (peginterferon beta-1a), disease modifying therapy for multiple sclerosis

NEUROLOGY - New medicinal product
Opinions on drugs - Posted on Aug 24 2015

Reason for request

Inclusion

No clinical benefit demonstrated in the treatment of the relapsing-remitting multiple sclerosis (RRMS) compared with existing treatments

 

  • PLEGRIDY has a Marketing Authorisation in the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS).
  • It is an alternative to other first-line disease modifying therapies indicated in RRMS.
  • Its efficacy versus placebo has been demonstrated. PLEGRIDY, administered subcutaneously once every 2 weeks, has not shown any clinical added value compared with available therapies.

Actual benefit

Important

-


Improvement in actual benefit

V (absence)

-


Therapeutic use

-

Contact Us

Évaluation des médicaments